Skip to content
MarketScale
‹ Back to IndustriesHealthcare

When Will International Travel Return?

No one thought back in March, when travel bans first went into effect, that we would still be here seven months later. The unfortunate thing is that many are questioning if there is an end in sight. A few factors, from a “second wave” of COVID-19 sweeping through Europe to a politically disruptive presidential campaign…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

No one thought back in March, when travel bans first went into effect, that we would still be here seven months later. The unfortunate thing is that many are questioning if there is an end in sight. A few factors, from a “second wave” of COVID-19 sweeping through Europe to a politically disruptive presidential campaign in the United States to a vaccine not being available yet, all of these huge factors into delaying opening up travel between Europe and the United States. Unfortunately, the reality of the situation is that international travel will unlikely open up this year.

That being said, there are many big organizations that are actively looking to find solutions to open up travel sooner than later.

A New Digital Health Passport is Looking to Restart Travel

Called, CommonPass, this program is already back by some big industry players like the U.S. Customs and Border Protection, American Express Global Business Travel, United & Cathay to name a few. CommonPass was developed by Swiss-based nonprofit the Commons Project and the World Economic Forum; it is being presented to 37 governments (and counting) as a way to help facilitate the reopening of borders and travel amid the coronavirus pandemic.

The purpose is to enable safer airline and cross-border travel by giving travelers and governments confidence in each traveler’s verified Covid-19 status, and provide a framework that sets standards for lab results and vaccination records, as well as a system that allows different countries to set their own health criteria for entry. But is this the answer to restarting travel, and can they convince governments that Covid-19 testing, not quarantines, is the best way to reopen borders? Time will tell.

Other interesting news in travel:

Canada Reopens Borders to Extended Families, Couples, and Students

While U.S.-Canadian border restrictions remain in effect through at least October 21, Canada’s government is working to soften the rules to accommodate certain types of travelers. Arrivals will still be required to quarantine, unless they’re specifically granted an exemption due to extenuating circumstances. Every visitor will need to apply for and receive official authorization before they can travel to Canada.

Rome’s Fiumicino Airport Awarded World’s First ” COVID-19 5-Star Airport Rating” from Skytrax

On September 1, the airport opened their own Covid testing center. The airport scored points for having easy-to-read signage in multiple languages, strict enforcement of mask wearing, and visibly present cleaning staff. For reference, three other airports have been awarded three stars for their Covid response – Malaga-Costa del Sol Airport (AGP) in Spain, Nice Côte d’Azur Airport (NCE) in France and London’s Heathrow Airport (LHR).

IHG Data is Showing That Younger Travelers Prefer Much Shorter Booking Windows

This will continue to prove to be a forecasting challenge, especially for labor and costs–note for all you travelers watching—yes, hotels do plan ahead for your arrival! They found that 63% percent of Americans now make reservations at an IHG hotel within two days of their stay compared to 39 % last year. Nearly 40% of British travelers are booking in that same two-day window compared to a little more than 20% last year.

Needless to say we are at an interesting time right now. More than just travelers, but businesses and governments are eager to get travel back up and running. But, simply put, we just aren’t there yet.

Say Yes To Travel has a new episode every Thursday!

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512